Stock Analysts

5 DuPont-Tested Stocks for a Winning Portfolio

In a market that may see a correction any time thanks to central banks’ moves and the consequent rising yields, geo-political concerns and overvaluation issues, picking the right stock is a task. The metric return on equity goes a long way in resolving this issue. The metric enables investors to differentiate between a profit-churner and a profit-burner […]

Stock Analysts

Vertex (VRTX) & Other Drug Stocks with FDA Catalysts this February

2017 turned out to be a notable year for the pharma and biotech industry with the FDA giving its nod to 46 novel drugs as well as several biological license applications (“BLA”) including for path-breaking cancer treatments like Kymriah and Yescarta. This number compares favorably not only to 2016 when just 22 novel drugs were approved, but to earlier years as well. Other key approvals last year include Lilly’s Verzenio (advanced or metastatic breast cancer), Gilead’s Vosevi (hepatitis C virus), Puma’s Nerlynx (to reduce the risk of breast cancer returning), J&J’s Tremfya (moderate-to-severe plaque psoriasis), Regeneron/Sanofi’s Kevzara (rheumatoid arthritis), Roche’s multiple sclerosis treatment, Ocrevus, Regeneron REGN and Sanofi’s eczema treatment, Dupixent, Tesaro’s PARP inhibitor, Zejula, and BioMarin’s BMRN Brineura (treatment of a specific form of Batten disease) among others […]

Mergers & Acquisitions

Golden Meditech Completes Sale of Equity Interest in China Cord Blood Corporation

Golden Meditech Completes Sale of Equity Interest in China Cord Blood Corporation PR Newswire HONG KONG, Jan. 31, 2018 HONG KONG , Jan. 31, 2018 /PRNewswire/ — Golden Meditech Holdings Limited (SEHK stock code: 00801) (the “Company”), a leading integrated healthcare enterprise in China , is pleased to announce that the sale of 65.4% of the issued share capital of China Cord Blood Corporation to Nanjing Yingpeng Huikang Medical Industry Investment Partnership (Limited Partnership) * has been completed. […]

Mergers & Acquisitions

The Ottawa Hospital Acquires Several Elekta Versa HD Devices for Advanced Cancer Treatment

The Ottawa Hospital Acquires Several Elekta Versa HD Devices for Advanced Cancer Treatment Innovative cancer treatment advancements on horizon for Ottawa patients PR Newswire STOCKHOLM, Jan. 31, 2018 STOCKHOLM , Jan. 31, 2018 /PRNewswire/ — Elekta (EKTA-B.ST) announced today that it has signed a strategic agreement with The Ottawa Hospital (TOH) in Ottawa, Ontario, Canada to deliver several Elekta Versa HD™ linear accelerators as well as software support and services […]

Mergers & Acquisitions

Fleet Complete acquires Ecofleet, advancing its expansion in Europe

Fleet Complete acquires Ecofleet, advancing its expansion in Europe PR Newswire TORONTO, Jan. 31, 2018 Company enters new markets in Scandinavia and Baltic states through acquisition of Ecofleet, reaching global subscriber base of over 400,000 TORONTO , Jan. 31, 2018 /PRNewswire/ – Fleet Complete , the fastest-growing provider of IoT solutions in the connected commercial vehicle space, announced today its acquisition of Ecofleet, the leading fleet telematics player in the Nordic and Baltic regions. […]

Mergers & Acquisitions

Camposol S.A. Announces that Merrill Lynch, Pierce, Fenner & Smith Incorporated Has Launched a Tender Offer and Consent Solicitation for Any and All of Camposol S.A.’s outstanding 10.50% Senior Secured Notes due 2021

Camposol S.A. Announces that Merrill Lynch, Pierce, Fenner & Smith Incorporated Has Launched a Tender Offer and Consent Solicitation for Any and All of Camposol S.A.’s outstanding 10.50% Senior Secured Notes due 2021 PR Newswire NEW YORK, Jan. 30, 2018 NEW YORK , Jan […]

Stock Analysts

Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX

The fourth-quarter 2017 earnings season is in full swing with financial figures from 133 S&P 500 members or 26% of the index already out as of Jan 26, 2018 per the latest Earnings Preview . Total earnings for these index members jumped 12.3% from the year-ago quarter, driven by 8.8% improvement in revenues. The beat ratio was 81.2% for the bottom line and 78.9% for the top line. […]

Stock Analysts

Post-Market Q4 Earnings Parade: SFLY, ALGN & More

Following today's closing bell, we see fresh quarterly earnings results from a host of new companies. As we've seen thus far in Q4 earnings season, results are generally better than expected, in some instances much more so. For instance, Zacks Rank #1 (Strong Buy)-rated Shutterfly SFLY is up 15% in after-hours trading following its big earnings beat reported this afternoon: $3.37 per share ($3.11 allowing for the one-time tax charge) on $593.8 million in revenues easily zipped past the $2.91 per share and $557 million, respectively […]

Mergers & Acquisitions

Stryve Foods LLC Becomes Major Player in the Protein Snack Industry With Acquisition of Biltong USA

Stryve Foods LLC Becomes Major Player in the Protein Snack Industry With Acquisition of Biltong USA PR Newswire PLANO, Texas, Jan. 30, 2018 PLANO, Texas , Jan. 30, 2018 /PRNewswire/ — Protein snacks start-up, Stryve Foods announced today that it acquired the assets of Biltong USA , one of the first USDA approved biltong manufacturers in the country […]

Mergers & Acquisitions

Thomson Reuters and Blackstone Announce Strategic Partnership for Thomson Reuters Financial & Risk (F&R) Business

Thomson Reuters and Blackstone Announce Strategic Partnership for Thomson Reuters Financial & Risk (F&R) Business PR Newswire TORONTO, Jan. 30, 2018 TORONTO , Jan. 30, 2018 /PRNewswire/ — Blackstone to acquire 55% interest in F&R with Thomson Reuters to retain 45% stake Values F&R business at ~$20 billion – Thomson Reuters to receive ~$17 billion in gross proceeds Partnership expected to strengthen F&R’s growth trajectory Reuters News remains part of Thomson Reuters: F&R to enter into 30-year agreement to secure access to news services provided by Reuters for a minimum of $325 million annually Thomson Reuters plans to use net proceeds to invest in its core Legal and Tax & Accounting units, pay down debt and repurchase shares Full-year 2017 results expected to meet or exceed guidance (to be released on February 8 ) On an IFRS basis, full-year revenues expected to increase 1%; Operating profit expected to increase approximately 25%; Diluted earnings per share (EPS) expected to decrease approximately 50% (as the prior-year period included $2 billion gain on the sale of IP & Science) Full-year adjusted EBITDA margin expected to be between 30.1% and 30.4% and Full-year adjusted EPS expected to be between $2.48 and $2.51 vs. […]